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ABSTRACT  
Autosomal recessive inherited ataxias are a growing group of genetic disorders. We report two 
Italian siblings presenting in their mid-50s with difficulty in walking, dysarthria and progressive 
cognitive decline. Visual loss, ascribed to glaucoma, manifested a few years before the other 
symptoms. Brain MRI showed severe cerebellar atrophy, prevalent in the vermis, with marked 
cortical atrophy of both hemispheres. Exome sequencing identified a novel homozygous mutation 
(c.935G>A;p.Ser312Asn) in the ceroid neuronal lipofuscinosis type 5 gene (CLN5). Bioinformatics 
predictions and in vitro studies showed that the mutation was deleterious and likely affects ER-
lysosome protein trafficking. Our findings support CLN5 hypomorphic mutations cause autosomal 
recessive cerebellar ataxia, confirming other reports showing CLN mutations are associated with 
adult-onset neurodegenerative disorders. We suggest CLN genes should be considered in the 
molecular analyses of patients presenting with adult-onset autosomal recessive cerebellar ataxia.  
INTRODUCTION 
The hereditary ataxias are a highly genetically heterogeneous group of disorders phenotypically 
characterized by gait ataxia, incoordination of eye movements, speech, and hand movements, and 
usually associated with cerebellar atrophy. Autosomal dominant forms typically have adult-onset; 
conversely autosomal recessive ataxias usually have onset in childhood [10]. Clinically and 
neuroradiologically these latter diseases overlap with milder forms of Neuronal Ceroid 
Lipofuscinosis (NCLs), a group of progressive neurodegenerative disorders characterized by the 
intralysosomal accumulation in both neural and peripheral tissues of autofluorescent, electron-dense 
cytoplasmic lipopigments (bearing close resemblance to lipofuscin)[1]. Clinically, NCLs are 
characterized by a variable combination of visual impairment, cerebellar ataxia, drug-resistant 
progressive myoclonic epilepsy, behavioral disturbances, mental deterioration, and early death [17]. 
NCLs are mainly transmitted with an autosomal recessive inheritance, though rare autosomal 
dominantly inherited forms have been described [11, 13, 23], and largely occur in infancy or 
preteen ages.  
At present, fourteen NCL forms are recognized, with 13 disease genes (named CLN) identified and 
more than 400 mutations reported (NCL Mutation Database: www.ucl.ac.uk/ncl/mutation).  
Here we describe an autosomal recessive form of adult-onset cerebellar ataxia associated with a 
novel CLN5 missense change in two siblings.  
 
MATERIALS AND METHODS 
We studied ATA-7-TO family originating from the North-West of Italy, in which the two affected 
sibling were born from first cousins parents. Genomic DNA was extracted from peripheral blood 
(Qiagen, Hilden, Germany) following the manufacturer instructions.  Molecular testing was 
negative for SCA1, SCA2, and Friedreich Ataxia. Exome sequencing and data analysis was 
performed implementing a previously described procedure [9] (see supplement).  
Validation of the mutation was performed by Sanger sequencing in all members of the family with 
primers designed to the exon 4 region of CLN5 (Reference sequence NM_006493,  NP_006484.1). 
Informed consent was obtained from all participants, . The study is a retrospective case report that 
does not require ethics committee approval. 
Human wild-type CLN5–pCMV (a.a. 1–407, CLN5-wt) and CLN5–pCMV carrying the Finnish 
major disease causing mutation p.Tyr392* (CLN5-fin) have previously been described [16]. The 
CLN5-Ser312Asn vector was generated by in vitro mutagenesis, using the Quick Change site 
directed mutagenesis kit (Stratagene, La Jolla, CA, USA). 
HEK293 cells were grown overnight on coverslips coated with gelatin 0.1% in 24-well chambers 
and cultivated in DMEM 10%FCS at 37°C and in presence of 5% CO2. Transient transfection with 
vectors containing CLN5-wt, CLN5-fin or CLN5-Ser312Asn cDNA was performed with Turbofect 
reagent (Thermo Fisher Scientific, Asheville, NC, USA) using the reported protocol [16] (see 
supplement).  
 
RESULTS 
The 55-year-old proband (III-6 in figure 1A) was a woman who presented with gait instability, 
dysarthria, and a mild cognitive deficit. Her past medical history had been unremarkable until she 
first sought neurological expert consultation after age 50 because of unsteady gait. Neurologic 
examination at age 58 was significant for a slight attention deficit, modest nystagmus with vertical 
component, dysarthric slurred speech, mild head tremor, and truncal ataxia. We also observed mild 
dysmetria and dysdiadochokinesia, an ataxic gait and posture, normal sensation, and brisk deep 
reflexes in the four limbs with normal plantar flexor response. Somatosensory evoked potentials, 
electroencephalogram (EEG), and nerve conduction velocities were all normal, as well as routine 
blood tests (including blood count, total cholesterol, alpha-fetoprotein and vitamin E levels) . 
Brain CT scan and MRI at age 58 showed a marked cerebellar atrophy (more evident in the vermis 
than the hemispheres) with a severe bilateral cortical atrophy - mainly parietal and temporal - 
without focal lesions (Figure 1B, C).   
At age 52, three years before recognition of her neurological symptoms, the patient complained 
visual problems that were initially attributed to glaucoma. Ophthalmological examination at age 58 
revealed a limited visual field in both eyes with a paracentral scotoma in the left eye. Fundoscopy 
disclosed a bilateral pale and excavated optic disc consistent with a severe galucoma but we could 
not exclude a previous lesion of the optic nerve. 
At the age of 61 years, the patient showed a worsening of her dysarthria, could not walk without 
help, and showed a severe intentional tremor in the four limbs. Upon appropriate testing, including 
an age/education-adjusted Mini Mental State Examination (MMSE) score of 19.4/30 , and a 
Montreal Cognitive Assessment score of 10/30, we also documented a more severe cognitive 
impairment with weakness especially in visual/spatial and executive tests, language, abstract 
symbolic reasoning and action planning. Conversely, time and space orientation, short term 
memory and calculation were relatively preserved. 
 
Her elder brother (patient III-5 in figure 1A) was first examined when he was 61 years old. He 
presented with gait problems and dysarthria since age 56 with a slight worsening over the past five 
years. Neurological evaluation showed an ataxic-spastic gait, nystagmus in all directions, dysarthria 
with slurred speech, marked dysmetria in the lower limbs, and brisk and symmetric deep reflexes in 
the limbs. Muscle strength and tone, as well as sensation, were not affected. A mild cognitive deficit 
was also evident at clinical examination, but the patient refused further neuropsychological testing.  
As for her sister, case III-6, also had glaucoma. Brain MRI was not available. 
 
We performed whole exome sequencing on III-5 and III-6 (71x and 68x coverage depth, 
respectively; sequencing statistics in Table S1). Assuming an autosomal recessive model of 
inheritance, we identified a single homozygous variant c.935G>A on chr13:77574815 in the CLN5 
gene, changing a Ser312 to Asn (NM_006493, OMIM *608102). This mutation was confirmed by 
Sanger sequencing (Figure 1D), in homozygosis in both affected siblings and in heterozygosis in 
the unaffected brother III-4.  
Serine 312 is a highly evolutionary conserved amino acid in vertebrates and it change was predicted 
to be deleterious using different bioinformatics tools (Table S2, figure S1). We evaluated the 
consequences of the p.Ser312Asn on CLN5 subcellular localization using immunofluorescence 
microscopy after HEK293 transfection (Figure 1E-G). Wild-type protein localized to lysosomal 
vesicles as expected [16], whereas both the CLN5-Ser312Asn and the CLN5-fin (Finnish mutation 
used as positive control) were retained in the Endoplasmic Reticulum (ER) compartment. Using 
cycloheximide, an inhibitor of cytoplasmic protein synthesis, we showed the complete disappearing 
of the fluorescence signal in cells carrying the CLN5-Ser312Asn indicating an intrinsic instability 
of the mutated proteins (Figure 1H-J). 
 
DISCUSSION 
Approximately 5% of the CLN mutations have been associated with adult-onset neurological 
phenotypes (from 17 to 43 yrs) divided into three different subtypes: Kufs diseases, characterized 
by progressive myoclonus epilepsy and cognitive decline (Type A), or behavioral anomalies, 
dementia, motor dysfunction, ataxia and extrapyramidal and suprabulbar signs (Type B) [4, 18]; 
adult NCLs which include autosomal dominant Parry disease due to DNJC5 mutations [13] and the 
recessive NCL type 11 associated with mutations in the progranulin gene [7](Table 1). 
Ataxia is the first symptom in adult-onset Neuronal Ceroid Lipofuscinosis, often followed by rapid 
cognitive deterioration, epilepsy and retinal degeneration.  
Using exome sequencing, we identified a homozygous c.935G>A (p.Ser312Asn) mutation in CLN5 
in two adult siblings initially presenting ataxia. Both bioinformatics analysis and functional studies 
in HEK293 cells support the pathogenetic role of the mutation. While the wild-type CLN5 co-
localize with lysosomes [16], the p.Ser312Asn mutant protein was retained in the ER and did not 
reach the lysosome, in analogy with p.Tyr392*, a previously well characterized CLN5 protein 
change causing an infantile-onset NCL in Finnish population. Therefore, our data further sustain the 
hypothesis that CLN5 mutations, including the one identified, impact the ER-lysosomal trafficking 
[15, 16]. 
Remarkably, both our cases had the onset of their neurological manifestations after 50 yrs in the 
form of cerebellar ataxia with mild cognitive impairment, and represent the most late-onset cases 
associated with CLN mutations. Although features of glaucoma in both patients might be related to 
other processes, including aging, it is tempting to assume that ocular manifestations were part of the 
neurodegenerative process [24]. Most CLN5 mutations result in a classical disease with onset 
between 4-7 yrs, and few mutations are also associated with juvenile to early-adult onset. Three 
cases were described with onset at 17 yrs, carrying respectively the p.Tyr258Asp homozygous 
mutation [8], or the compound heterozygous  p.Cys126Tyr / p.Tyr374Cys or p.Thr303CysfsX10 / 
p.Tyr374Cys mutations [24]. CLN5 disease-causing mutations are spread through the gene, and 
include missense, splicing and nonsense alterations (www.ucl.ac.uk/ncl/mutation). We hypothesize 
that the amino acid position and/or the chemical-physical change seen in our patients behaves as 
hypomorphic because it has a less severe impact on the protein function as compared to the other 
CLN5 variants.  
TPP1, whose canonical mutations cause NCL2, has also been recently associated with autosomal 
recessive ataxia SCAR7 [20], suggesting the existence of a novel category of adult-onset diseases 
associated with CLN mutations, presenting with cerebellar ataxia and progressive cognitive decline. 
These data indicate that CLN2 and CLN5  may be suspected in case of adult-onset autosomal 
recessive cerebellar ataxia, and foresees the identification of further CLN involved in adult-onset 
phenotypes.  
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FIGURE LEGENDS 
Figure 1. Pedigree, brain MRI, mutation and cellular analyses.  
A. Pedigree of family ATA-7-TO suggested an autosomal recessive transmission due to parents 
consanguinity. B and C. Axial and sagittal T1-weighted brain resonance magnetic images in patient 
II-5 at 58 yrs. A marked cerebellar hemispheric and a more severe vermian atrophy is present. 
Supratentorial atrophy is also evident. D Mutation c.935G>A; p.Ser312Asn, affects a highly 
conserved amino acid (interspecies protein alignment is reported in figure S1). Panels E-J, 
localization of the p.Ser312Asn CLN5 mutant protein in HEK293 transfected cells. E-G. HEK293 
cells transfected with human wild-type CLN5, CLN5-fin and CLN5-Ser312Asn mutants 
respectively. Immunostaining using rabbit antibody against CLN5 (1RmI-4) shows a diffuse 
punctate patter for wild-type protein consistent with its known lysosomal localization [16] (panel 
E). Both mutants show a diffuse reticular staining, compatible with a ER retention (panels F and G). 
Panels H-J illustrate the effect of cycloheximide treatment on CLN5 protein turnover (green). After 
three hours incubation with cycloheximide wild-type CLN5 maintains a lysosomal localization, 
while CLN5-fin and CLN5-Ser312Asn mutants completely disappear from ER, as demonstrated by 
counter-staining with the ER marker PDI (in red).  
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 Table 1. Adult onset forms of neuronal Ceroid Lipofuscinosis 
NCL 
category 
GENE 
Inheri-
tance 
Mutation 
Number 
of 
Cases 
Age 
at 
onset 
(yrs) 
Phenotype at onset Ref. 
A
N
C
L
 
CLN1 (PPT) AR 
p.Arg151* 
p.Gly108Arg 
2 31-38 
Psychiatric symptoms followed by ataxia, visual, 
verbal, and cognitive losses 
[21] 
CLN1 (PPT) AR 
p.Arg151* 
p.Cys45Tyr 
1 24 n.a. [14] 
CLN4a (DNAJC5) AD p.Leu115Arg 1 34 Seizure, progressive dementia [13] 
CLN4b (DNAJC5) AD p.Leu116del 1 25 Behavioural anomalies, seizure dementia, speech 
regression followed by ataxia 
[13] 
CLN5 AR 
p.Cys126Tyr 
p.Tyr374Cys 
1 17 Cognitive regression and visual loss followed by 
seizure and motor difficulty 
[24] 
CLN5 AR 
p.Tyr303Cysfs*10 
p.Tyr374Cys 
1 17 
Motor difficulty followed by seizure, visual loss and 
cognitive regression 
[5] 
CLN6 AR 
p.Tyr93Met 
p.Leu128Val 
1 n.a. n.a. [12] 
CLN11 (GRN) AR p.Thr272Serfs*10 2 22-23 Visual failure and convulsion followed by ataxia [19] 
T
y
p
e
 A
 K
D
 
CLN4a (DNAJC5) AD p.Leu116del 1 26 Behavioural anomalies, followed by seizures [22] 
CLN4a (DNAJC5) AD p.Leu116del 19 26-40 Myoclonus, Speech deterioration, Ataxia, Dementia [6] 
CLN4a (DNAJC5) AD p.Leu115Arg 1 43 Myoclonus, Speech deterioration, Ataxia, Dementia [6] 
 CLN4a (DNAJC5) AD p.Leu116del 10 28-33 
Myoclonus, Seizures, cognitive deterioration 
followed by motor impairment 
[13] 
CLN6 AR p.Leu47Phe 1 28 
Myoclonus followed by ataxia and dementia. No 
visual loss. 
[2] 
CLN6 AR p.Arg6Thr 1 31 
Seizures followed by myoclonus and dementia. No 
visual loss. 
[2] 
CLN6 AR 
p.Leu67Pro 
p.Arg103Gln 
2 16-26 
Myoclonus followed by seizures and dementia. No 
ataxia nor visual loss. 
[2] 
CLN6 AR p.Phe238Thr 3 17-51 Myclonus, ataxia and cognitive decline [2] 
CLN6 AR 
p.Tyr50* 
p.Asn77Lys 
p.Ser308Thr 
1 n.a. n.a. [2] 
CLN6 AR 
p.Arg149His  
p.Pro297Leufs*53 
2 35-43 Seizure or ataxia followed by tremor and dementia [2] 
T
y
p
e
 B
 K
D
 
CLN4b (DNAJC5) AD p.Leu115Arg 1 25 Behavioral anomalies, dementia [3] 
CLN6 AD p.Ala34Thr 1 37 Dementia followed by seizures [2] 
CLN13 (CTSF) AR p.Gln321Arg 1 24 Seizures. Vision preserved [18] 
CLN13 (CTSF) AR 
p.Gly458Ala 
p.Ser480Leu 
2 22-32 Progressive cerebellar syndrome, ataxia, 
dysarthria. Vision preserved 
[18] 
CLN13 (CTSF) AR 
p.Tyr231Cys 
p.Ser319Leufs*27 
1 35 
Cognitive decline, mild dysarthria, mild gait ataxia 
with tremor. 
[18] 
Figure 1. 
 
Supplement 
Materials and methods 
Exome sequencing data analysis 
Briefly, we captured exonic regions from genomic DNA by using Agilent SureSelect Human All 
Exon kit, and performed pair-end sequencing on an Illumina HiSeq 2000. We followed two 
independent analysis workflows to perform sequencing read alignment, variant calling and variant 
annotation. In the first pipeline (P1), we employed Burrows-Wheeler alignment to map fastq files to 
the human reference genome (UCSC hg19)[11]. We called variants using Genome Analysis Tool 
Kit (GATK, version 1.4) [12] followed by functional annotation with Annovar [13] and SnpEff 
[14]. In the second pipeline (P2), we conducted alignment to UCSC hg19 by Short Oligonucleotide 
Analysis Package (SOAP, version2.21) [15], then used SOAPsnp (version 1.05) [16] to identify 
single nucleotide variants (SNVs) as well as GATK [12] to detect small insertion-deletions (indels). 
We annotated variants by BGI’s self-developed scripts in the second pipeline.  
We assumed an autosomal recessive inheritance model, and filtered variants generated in each 
pipeline, as described in supplement.  
First we retained homozygous mutations shared by both affected individuals, and excluded variants 
that meet any of the following criteria: 1) intronic regions >20bp from exon boundaries; 2) 
synonymous changes; 3) minor allele frequency (MAF) > 0.5% in one of the following databases: 
dbSNP135 (http://www.ncbi.nlm.nih.gov/snp), 1000 Genomes Project (n = 1,092 genotyped 
samples) (www.1000genomes.org), HapMap Project (n = 1,301 genotyped samples) 
(http://hapmap.ncbi.nlm.nih.gov), NHLBI Exome Sequencing Project (n = 6,500 exomes) 
(https://esp.gs.washington.edu/drupal/), CAG-CHOP (n = 669 exomes), or BGI internal controls (n 
= 1,414). We particularly considered variants close to splice sites and frameshift indels. Next, we 
prioritized the resulting variant list according to evolutionary conservation and filtered out regions 
with PhyloP [18] value<0.95; then retained variants predicted as “deleterious/damaging” by 
PolyPheN [19] and SIFT [20]. At last, we considered biological and clinical relevance of cerebellar 
ataxia for the identified candidates.  
 
Immunofluorescence 
Forty-eight hours after transfection, cells were fixed in ice-cold methanol for 3 min and then 
blocked with 0.5% bovine serum albumin (BSA) in phosphate buffered-saline (PBS) for 30 
minutes. In the cycloeximide experiment, cells were treated with 50µg/ml cycloheximide (Sigma-
Aldrich, St. Louis, Missouri, USA) to stop protein synthesis for three hours prior to fixing. For co-
localization studies we used primary antibodies against PDI for ER staining (1:200) (Sigma-
Aldrich, St. Louis, Missouri, USA). CLN5 –antibody (1RmI-4) was used with dilutions previously 
reported in [21]. Primary and secondary antibodies were diluted in blocking buffer and incubated 
for 1 hr respectively at 37°C or room temperature. Stained coverslips were visualized using 
Olympus confocal microscope (Olympus, Center Valley, PA, 18034, USA). 
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Table S1. Sequencing summary statistics for the samples, as well as variant numbers called by CAG and BGI pipelines P1 and P2, 
respectively. Qualified variants mean those fall in exonic regions or at splicing donor/recipient sites. 
Sample 
Family 
relation 
ship 
Total reads 
mapped to 
genome (Mb) 
Total data 
on target 
region (Gb) 
Mean depth 
of target 
region 
Coverage of 
target region 
(%) 
Total SNV's 
called (P1/P2) 
Qualified 
SNV's 
called 
(P1/P2) 
Total indel's 
called 
(P1/P2) 
Qualifie
d indel's 
called 
(P1/P2) 
III-5 
Affected 
brother 
41.67 3.15 68.50 98.82 39,981/79,214 
16,366/17,5
67 
6,388/5,926 620/697 
III-6 
Affected 
sister 
43.38 3.26 71.11 98.98 44,979/84,423 
16,682/17,9
80 
7,060/6,237 630/718 
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Table S2: In silico prediction of the p.Ser312Arg mutation on CLN5 protein  
Software Score Predicted effect Web site 
SIFT  0 Deleterious http://sift.bii.a-star.edu.sg/ 
Mutation T@ster 46 Disease causing www.mutationtaster.org/ 
MAPP 0.001664 Bad http://mendel.stanford.edu/sidowlab/downloads/MAPP/index.html 
Polyphen 2 1.0 Probably Damaging www.genetics.bwh.harvard.edu/pph2/ 
I-MUTANT 2 Reduced Stability http://folding.biofold.org/i-mutant/i-mutant2.0.html 
 
 
Figure S1. Evolutionary conservation of Serine 312 in vertebrates 
 
 
 
